FDA seen tougher on drug risks post-Avandia
NEW YORK - Regulators appear to be increasing their scrutiny of product risks after cases like the bitter debate over the diabetes pill Avandia, industry executives and experts said this week.
Analysis: Sluggish medical device sector ripe for mergers
NEW YORK - The stage is set for more dealmaking in the medical device sector, with companies eager to find faster growth amid a stubbornly weak economy and potential targets still attractively valued.
AstraZeneca CEO wary of U.S. FDA budget cuts
NEW YORK - Sharp cuts in taxpayer funding for the U.S. Food and Drug Administration could hurt pharmaceutical companies that want faster reviews of their products, AstraZeneca Plc's chief executive said on Wednesday.
Analysis: Health insurers shake up model after U.S. overhaul
NEW YORK - Become tech-savvy. Bulk up. Venture abroad.
Health overhaul should press ahead: industry
NEW YORK - Repeal reform? No thanks, say health insurers, drugmakers and others looking for a clearer picture of the U.S. healthcare market after the bruising passage of the controversial overhaul law.
Analysis: Drug industry doses up on emerging markets
NEW YORK - Big Pharma's drive into emerging markets could make drugmakers look a lot more like consumer goods companies in future. That may be no bad thing.
Analysis: Americans make slow return to doctor's offices
NEW YORK - Americans are slowly making their way back to the doctor's office after many months of skimping on medical care, holding off on everything from routine visits to hip replacements.
New Aetna CEO brings style shift to insurer
NEW YORK - Aetna Inc President Mark Bertolini, who becomes CEO later this month, has half the kidneys and twice the energy of an ordinary human being and is set to take on the Herculean task of trying to change the health insurance industry's villainous image. | Video
Health Summit quotes of the day
Following is a selection of quotes from the Reuters Health Summit: | Video
Analysis: Top-name drug recalls a bitter pill for consumers
NEW YORK - With bugs in baby formula, glass flakes in intravenous drugs and foul odors emanating from Lipitor and children's Tylenol, a steady stream of high profile product recalls is undermining confidence in top drugmakers.
Analysis: Genzyme seen an anomaly in bite-sized market
NEW YORK - Sanofi-Aventis' $18.5 billion pursuit of Genzyme Corp may be a foregone conclusion for many healthcare industry executives and bankers, but few rivals likely will copy the hostile bid.
Speakers
| Summit | Date | Category |
|---|---|---|
| Aerospace and Defense | Sep 3 - 5 | Aerospace/Defense |
| Global Consumer and Retail | Sep 9 - 12 | Consumer Retail |
| Russia Investment | Sep 23 - 25 | Financial Services/Exchanges |
| Washington | Oct 21 - 24 | Country Summits |
| Middle East Investment | Oct 28 - 30 | Financial Services/Exchanges |
| Global Commodities | Nov 4 - 7 | Financial Services/Exchanges |
| Global Investment Outlook | Nov 18 - 21 | Financial Services/Exchanges |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
